Impaired immune phenotype of circulating endothelial-derived microparticles in patients with metabolic syndrome and diabetes mellitus

Journal of Endocrinological Investigation

Volumn 38, Issue 8, 2015, Pages 865-874

  Berezin, A E ^a   Kremzer, A A ^a   Samura, T A ^a   Berezina, T A ^b   Kruzliak, P ^c  

^a ZAPORIZHZHIA STATE MEDICAL UNIVERSITY   (Ukraine)

^b Private Medical Center Vita Center   (Ukraine)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Cardiovascular risk factors; Circulating endothelial derived microparticles; Diabetes mellitus; Metabolic syndrome

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD31 ANTIGEN; CD62E ANTIGEN; LIPOCORTIN 5; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CYTOKINE PRODUCTION; DYSLIPIDEMIA; ENDOTHELIAL MICROPARTICLE; FEMALE; HEMODYNAMIC PARAMETERS; HUMAN; IMMUNOPHENOTYPING; INFLAMMATION; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; BLOOD; DIABETES MELLITUS, TYPE 2; IMMUNOLOGY; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; PHENOTYPE; RETROSPECTIVE STUDY; RISK FACTOR; VASCULAR ENDOTHELIUM;

ADULT; CELL-DERIVED MICROPARTICLES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHENOTYPE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84937436564     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-015-0273-z     Document Type: Article

References (51)

1. Nichols GA, Schroeder EB, Karter AJ, Gregg EW, Desai J, Lawrence JM, O'Connor PJ, Xu S, Newton KM, Raebel MA, Pathak RD, Waitzfelder B, Segal J, Lafata JE, Butler MG, Kirchner HL, Thomas A, Steiner JF, SUPREME-DM Study Group (2015) Trends in diabetes incidence among 7 million insured adults, 2006-2011: the SUPREME-DM project. Am J Epidemiol 181(1):32-39
2. Szczerbińska K, Topinková E, Brzyski P, van der Roest HG, Richter T, Finne-Soveri H, Denkinger MD, Gindin J, Onder G, Bernabei R (2014) The characteristics of diabetic residents in European nursing homes: results from the SHELTER study. J Am Med Dir Assoc. doi: 10.1016/j.jamda.2014.11.009 (epub ahead of print)
3. Eliasson B, Gudbjörnsdottir S (2014) Diabetes care - improvement through measurement. Diabetes Res Clin Pract 106(2):S291-S294
4. Eschwege E, Basdevant A, Crine A, Moisan C, Charles M (2014) Type 2 diabetes mellitus in France in 2012: results from the ObEpi survey. Diabetes Metab. doi: 10.1016/j.diabet.2014.11.007 (epub ahead of print)
5. Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813-823
6. Huber CA, Diem P, Schwenkglenks M, Rapold R, Reich O (2014) Estimating the prevalence of comorbid conditions and their effect on health care costs in patients with diabetes mellitus in Switzerland. Diabetes Metab Syndr Obes 7:455-465
7. McMurray SD (2014) The fight against diabetes: how the kidney care community is taking action. Nephrol News Issues 28(10):30-32
8. Moreno PR, Fuster V (2004) New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 44(12):2293-2300
9. Wong ND, Patao C, Malik S, Iloeje U (2014) Preventable coronary heart disease events from control of cardiovascular risk factors in US adults with diabetes (projections from utilizing the UKPDS risk engine). Am J Cardiol 113(8):1356-1361
10. van Sloten TT, Henry RM, Dekker JM, Nijpels G, Unger T, Schram MT, Stehouwer CD (2014) Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the Hoorn study. Hypertension 64(6):1299-1305
11. Jia G, Sowers JR (2014) Endothelial dysfunction potentially interacts with impaired glucose metabolism to increase cardiovascular risk. Hypertension 64(6):1192-1193
12. Zaghloul A, Al-Bukhari TA, Al-Pakistani HA, Shalaby M, Halawani SH, Bajuaifer N, Teama SH (2014) Soluble endothelial protein C receptor and high sensitivity C reactive protein levels as markers of endothelial dysfunction in patients with type 1 and type 2 diabetes mellitus: their role in the prediction of vascular complications. Diabetes Res Clin Pract 106(3):597-604
13. Markiewicz M, Richard E, Marks N, Ludwicka-Bradley A (2013) Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases. J Aging Res 2013:734509
14. Barteneva NS, Fasler-Kan E, Bernimoulin M, Stern JN, Ponomarev ED, Duckett L, Vorobjev IA (2013) Circulating microparticles: square the circle. BMC Cell Biol 14:23
15. Guay C, Regazzi R (2015) Role of islet microRNAs in diabetes: which model for which question? Diabetologia 58(3):456-463
16. Wu ZH, Ji CL, Li H, Qiu GX, Gao CJ, Weng XS (2013) Membrane microparticles and diseases. Eur Rev Med Pharmacol Sci 17(18):2420-2427
17. Tetta C, Bruno S, Fonsato V, Deregibus MC, Camussi G (2011) The role of microvesicles in tissue repair. Organogenesis 7(2):105-115
18. Martinez MC, Andriantsitohaina R (2011) Microparticles in angiogenesis: therapeutic potential. Circ Res 109:110-119
19. Rautou PE, Vion AC, Amabile N, Chironi G, Simon A, Tedgui A, Boulanger CM (2011) Microparticles, vascular function, and atherothrombosis. Circ Res 109(5):593-606
20. Kurtzman N, Zhang L, French B, Jonas R, Bantly A, Rogers WT, Moore JS, Rickels MR, Mohler ER 3rd (2013) Personalized cytomic assessment of vascular health: evaluation of the vascular health profile in diabetes mellitus. Cytometry B Clin Cytom 84(4):255-266
21. (2013) Executive summary: standards of medical care in diabetes - 2013. Diabetes Care 36(1):S4-S10
22. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106(25):3143-3421
23. Bluemke DA, Achenbach S, Budoff M, Gerber TC, Gersh B, Hillis LD, Hundley WG, Manning WJ, Printz BF, Stuber M, Woodard PK (2008) Noninvasive coronary artery imaging: magnetic resonance angiography and multidetector computed tomography angiography: a scientific statement from the American heart association committee on cardiovascular imaging and intervention of the council on cardiovascular radiology and intervention, and the councils on clinical cardiology and cardiovascular disease in the young. Circulation 118:586-606
24. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604-612
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
26. Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E (2012) Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care 35(7):1605-1610
27. Berezin AE, Kremzer AA (2014) Relationship between circulating endothelial progenitor cells and insulin resistance in none-diabetic patients with ischemic chronic heart failure. Diabetes Metab Syndr Clin Res Rev 8:138-140
28. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499-502
29. Orozco AF, Lewis DE (2010) Flow cytometric analysis of circulating microparticles in plasma. Cytometry A 77(6):502-514
30. Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George F (2013) The ISTH SSC workshop. standardization of pre-analytical variables in plasma microparticle determination: results of the international society on thrombosis and haemostasis SSC collaborative workshop. J Thromb Haemost. doi: 10.1111/jth.12207 (epub ahead of print)
31. Leroyer AS, Tedgui A, Boulanger CM (2008) Microparticles and type 2 diabetes. Diabetes Metab 34(1):S27-S32
32. Amabile N, Cheng S, Renard JM, Larson MG, Ghorbani A, McCabe E, Griffin G, Guerin C, Ho JE, Shaw SY, Cohen KS, Vasan RS, Tedgui A, Boulanger CM, Wang TJ (2014) Association of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham heart study. Eur Heart J 35(42):2972-2979
33. Nomura S (2009) Dynamic role of microparticles in type 2 diabetes mellitus. Curr Diabetes Rev 5(4):245-251
34. Puddu P, Puddu GM, Cravero E, Muscari S, Muscari A (2010) The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol 26(4):140-145
35. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS (2003) Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 109(4):175-180
36. Arteaga RB, Chirinos JA, Soriano AO, Jy W, Horstman L, Jimenez JJ, Mendez A, Ferreira A, de Marchena E, Ahn YS (2006) Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiology 98(1):70-74
37. Eaton S (2006) Release and trafficking of lipid-linked morphogens. Curr Opin Genet Dev 16:17-22
38. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A (2009) Endothelial microparticles in diseases. Cell Tissue Res 335(1):143-151
39. Shantsila E (2009) Endothelial microparticles: a universal marker of vascular health? J Hum Hypertens 23:359-361
40. Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C (2011) Exosome/microvesiclemediated epigenetic reprogramming of cells. Am J Cancer Res 1:98-110
41. Théry C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9:581-593
42. Poulsen MK, Nybo M, Dahl J, Hosbond S, Poulsen TS, Johansen A, Høilund-Carlsen PF, Beck-Nielsen H, Rasmussen LM, Henriksen JE (2011) Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. Cardiovasc Diabetol 10:76-84
43. Müller G, Schneider M, Biemer-Daub G, Wied S (2011) Microvesicles released from rat adipocytes and harboring glycosylphosphatidylinositol-anchored proteins transfer RNA stimulating lipid synthesis. Cell Signal 23(7):1207-1223
44. Wang Y, Chen LM, Liu ML (2014) Microvesicles and diabetic complications - novel mediators, potential biomarkers and therapeutic targets. Acta Pharmacol Sin 35(4):433-443
45. Jansen F, Yang X, Hoelscher M, Cattelan A, Schmitz T, Proebsting S, Wenzel D, Vosen S, Franklin BS, Fleischmann BK, Nickenig G, Werner N (2013) Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 128(18):2026-2038
46. Sinning JM, Losch J, Walenta K, Böhm M, Nickenig G, Werner N (2011) Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J 32(16):2034-2041
47. Mause SF, Weber C (2010) Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 107(9):1047-1057
48. Montoro-García S, Shantsila E, Marín F, Blann A, Lip GY (2011) Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. Basic Res Cardiol 106(6):911-923
49. Berezin AE (2014) Circulating endothelial-derived apoptotic microparticles as novel perspective biomarker for diabetes. Diabetes Res Treat Open Access 1(4):117-120. doi: 10.14437/DRTOA-1-117
50. Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA (2015) The predictive role of circulating microparticles in patients with chronic heart failure. BBA Clin 3:18-24
51. Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA (2014) The biomarker risk prediction score in chronic heart failure. J Dis Mark 1(1):8